Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor

Model NO.
D-sung Ticagrelor
Shelf Life
2 Years
CAS No.
274693-27-5
Test Method
HPLC
Specific
COA
Melting Point
149-154 °c
Density
1.67
MW
522.57
Mf
C23h28f2n6o4s
Grade
Pharmaceutical Grade
Color
White
Application
Antiplatelet;Treatment Acute Coronary
Product Name
Ticagrelor
Appearance
White Powder
Assay
HPLC 99%
Name
Ticagrelor Powder
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month
Reference Price
$ 45.00 - 72.00

Product Description

Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor
Pharmaceutical   CAS 274693-27-5   Ticagrelor   Powder Purity   Ticagrelor Material   Ticagrelor
Product Description
Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor
Product Details
Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor
Product name Ticagrelor
Cas number 274693-27-5
Apperance White powder
MF C23H28F2N6O4S
MW 522.57
Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.

It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
Application&Function
Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor

Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.The drug was approved by the US Food and Drug Administration on July 20, 2011.
Ticagrelor is an antagonist of the P2Y12 receptor.

Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.

Specification

Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor
Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor Pharmaceutical CAS 274693-27-5 Ticagrelor Powder Purity Ticagrelor Material Ticagrelor

 

 

LEGALIS.IT, 2023